Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328219 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2KMT2APOLBRAB9AKDM4E | |
| SCHEMBL29627992 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL3421898 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL20058170 | 0.82 | CSNK2A1 (0.62) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL5885098 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL13407497 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL24299170 | 0.80 | POLB (0.40) | SMN1; SMN2HSD17B10POLBGAAKDM4E | |
| SCHEMBL879116 | 0.80 | GAA (0.58) | MEN1KMT2APOLBGAACSNK2A1 | |
| SCHEMBL1003542 | 0.80 | GAA (0.58) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL827985 | 0.80 | SORT1 (0.46) | POLBGAARAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116529235-A | Fungicidal aryl amidines | 科迪华农业科技有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2021253098-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| EP-2791137-B1 | PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION PROCESS THEREFOR AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2019-01-23 | — | — | EP | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARM LTD (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9102670-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-20060058374-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-03-16 | — | — | US | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20040077529-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003104216-A1 | UROTENSIN II RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-4107311-A | ANTI-FERTILITY AGENTS, ABORTIFACIENTS | SANDOZ, INC. (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077529-A1 | Urotensin II receptor agents | UTS2R, PLAUR, GPR17 | SMN1; SMN2 2013/4885HSD17B10 3202/4885MEN1 2556/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | SMN1; SMN2 27/4885HSD17B10 3854/4885MEN1 786/4885 |
| US-20060058374-A1 | Urotensin II receptor agents | UTS2R, PLAUR, SCTR | SMN1; SMN2 2240/4885HSD17B10 3346/4885MEN1 2755/4885 |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | SMN1; SMN2 2237/4885HSD17B10 3431/4885MEN1 872/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | SMN1; SMN2 37/4885HSD17B10 3472/4885MEN1 1171/4885 |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MTOR, RICTOR, RPTOR | SMN1; SMN2 2237/4885HSD17B10 3431/4885MEN1 872/4885 |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | SMN1; SMN2 2237/4885HSD17B10 3431/4885MEN1 872/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | SMN1; SMN2 1563/4885HSD17B10 20/4885MEN1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.